TABLE 19-7.
Miscellaneous Drugs Used in the Neonatal Intensive Care Unit
| DRUG | DOSE | ROUTE | FREQUENCY | COMMENTS |
|---|---|---|---|---|
| Aminophylline | 2–3 mg/kg | IV* | b.i.d. to q.i.d. | Monitor theophylline levels. Therapeutic: 6–12 μg/l Toxic: >20 μg/l |
| Caffeine | 10 mg/kg loading dose 2.5 mg/kg maintenance | Orally as needed | s.i.d., b.i.d. | Steady state level: 5–20 μg/l Toxic: >50–75 μg/l |
| Dimethyl sulfoxide | 1 g/kg | IV | Once | Administer as 5% to 10% solution; dimethyl sulfoxide is hypertonic. |
| Heparin | 40–100 U/kg | SQ/IV | b.i.d. | — |
| Insulin (protamine zinc) | 0.15 U/kg | IM/SQ | b.i.d. | — |
| Insulin (regular) | 0.00125–0.2 U/kg/hr | IV | Constant rate Infusion | Pretreat lines: insulin adsorbs to lines. |
IV, Intravenous; SQ, subcutaneous; IM, intramuscular.
Adapted from Palmer JE: Neonatal drug doses. Proceedings of the International Veterinary Emergency Critical Care Symposium, San Antonio, Tex., 2000.
© 2004
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.